Patents Issued in October 24, 2024
  • METHODS OF ADMINISTERING SOLRIAMFETOL TO LACTATING WOMEN
    Publication number: 20240350435
    Abstract: Provided herein according to some embodiments is a method for decreasing the potential for adverse events from solriamfetol in an infant fed breast milk obtained from a subject treated with solriamfetol comprising: orally administering the solriamfetol to the subject at a daily dose of about 37.5 mg to about 300 mg; and feeding the infant breast milk from the subject at least about 5 hours after administering the solriamfetol to the subject, thereby decreasing potential for adverse events from solriamfetol in an infant.
    Type: Application
    Filed: June 28, 2024
    Publication date: October 24, 2024
    Inventor: Herriot TABUTEAU
  • METHODS FOR HAIR GROWTH
    Publication number: 20240350436
    Abstract: The present disclosure provides for treating hair loss (e.g., inducing or promoting hair growth or regrowth) and promoting or activating hair follicle development (e.g., generating new hair follicles or hair follicle stem cells). More particularly, the present disclosure provides methods comprising administration of PTEN inhibitors (e.g., vanadate derivatives (e.g., bisperoxovanadium salts) to a subject.
    Type: Application
    Filed: July 14, 2022
    Publication date: October 24, 2024
    Inventors: Rogerio M. Castilho, Cristiane H. Squarize
  • GAMMA-HYDROXYBUTYRATE COMPOSITIONS HAVING IMPROVED PHARMACOKINETICS IN THE FED STATE
    Publication number: 20240350437
    Abstract: Oral pharmaceutical compositions of sodium oxybate having improved pharmacokinetic properties when administered less than two hours after eating are provided, and therapeutic uses thereof.
    Type: Application
    Filed: June 28, 2024
    Publication date: October 24, 2024
    Inventors: Julien Grassot, Cendrine Grangeon, Jordan Dubow
  • GAMMA-HYDROXYBUTYRATE COMPOSITIONS HAVING IMPROVED PHARMACOKINETICS IN THE FED STATE
    Publication number: 20240350438
    Abstract: Oral pharmaceutical compositions of sodium oxybate having improved pharmacokinetic properties when administered less than two hours after eating are provided, and therapeutic uses thereof.
    Type: Application
    Filed: June 28, 2024
    Publication date: October 24, 2024
    Inventors: Julien Grassot, Cendrine Grangeon, Jordan Dubow
  • CALCIUM LACTATE COMPOSITIONS AND METHODS OF USE
    Publication number: 20240350439
    Abstract: The invention relates to pharmaceutical compositions comprising calcium lactate as an active agent and a polysaccharide, polymer, lipid, or a combination thereof. The pharmaceutical compositions are useful treating cancer. The invention also relates to foods and nutrient compositions comprising calcium lactate.
    Type: Application
    Filed: June 28, 2024
    Publication date: October 24, 2024
    Applicant: METIMEDI PHARMACEUTICALS CO., LTD.
    Inventors: Chong Hwan CHANG, Keun-Yeong JEONG
  • EXTRACTION OF ABSCISIC ACID FROM STRAWBERRIES
    Publication number: 20240350440
    Abstract: The disclosure of the present patent application relates generally to the extraction and purification of abscisic acid (ABA) from strawberries and its application in medicine and disease treatment in mammals and specifically humans. The extraction and purification process uses gel column chromatography to provide a highly pure composition of ABA, and the application of such includes treating heart disease.
    Type: Application
    Filed: July 17, 2023
    Publication date: October 24, 2024
    Inventors: HANY MOHAMED ABD EL-LATEEF AHMED, MAI MOSTAFA KHALAF ALI, AHMED MOHAMMED ABU-DIEF MOHAMMED, HAZEM MOHAMED SHAHEEN, GABER ELSABER ABD EL-WANIS BATIHA, MANAL ALY SHALABY, RASHA MANSOUR NAGI
  • PHARMACEUTICAL FORMULATION AND A PROCESS FOR ITS PREPARATION
    Publication number: 20240350441
    Abstract: The present disclosure relates to a pharmaceutical formulation and a process for its preparation. The pharmaceutical formulation comprises cinnamic acid and at least one excipient. The pharmaceutical formulation of the present disclosure has improved patient compliance, and reduced adverse effects. The pharmaceutical formulation of the present disclosure can be used in the treatment of cyclophosphamide induced neutropenia. The present disclosure further relates to a process of preparing the cinnamic acid. The process is simple and economical.
    Type: Application
    Filed: March 30, 2022
    Publication date: October 24, 2024
    Inventors: Sriram PADMANABHAN, Vinod Ramchandra JADHAV
  • METHODS OF TREATING CANCER
    Publication number: 20240350442
    Abstract: The invention features methods of treating cancer with ?-GPA. The disclosure also provides methods of treating cancer including combinations of ?-GPA and additional anti-cancer therapies.
    Type: Application
    Filed: May 2, 2024
    Publication date: October 24, 2024
    Inventors: Masoud Fakhr TAVAZOIE, David M. DARST, JR., Foster Casimir GONSALVES, Isabel KURTH
  • COMPOSITION, FORMULATION, PREPARATION METHOD AND USE FOR GLUTATHIONE PRECURSOR
    Publication number: 20240350443
    Abstract: A composition, formulation, preparation method and use for a glutathione precursor. The composition comprises, in parts by weight: a selenium-containing compound; a glutathione precursor; a zinc-containing compound. A powder obtained by mixing the present composition has good mixing uniformity and good fluidity, and facilitates filling in a filling capsule; and a capsule containing the composition has the effects of liver protection, oxidation resistance, and immunity enhancement.
    Type: Application
    Filed: August 9, 2022
    Publication date: October 24, 2024
    Inventors: Lei YANG, Chengjun ZHU, Wenwen ZHANG, Panpan XING, Xiaomeng WANG, Haixia SU, Liyan ZHA, Dawei LIU, Hao FENG
  • COMBINATION COMPRISING DECANOIC ACID FOR THE TREATMENT OF EPILEPSY
    Publication number: 20240350444
    Abstract: Decanoic acid for use in treating epilepsy wherein the decanoic acid is used in combination with perampanel, or a pharmaceutically acceptable salt thereof, or wherein the decanoic acid is used in combination with an AMPA receptor inhibitor that binds to the same AMPA receptor site as perampanel.
    Type: Application
    Filed: June 27, 2024
    Publication date: October 24, 2024
    Applicant: UCL BUSINESS LTD
    Inventors: Robin Simon Brooke Williams, Matthew Walker
  • ANTI-FUNGAL COMPOSITIONS
    Publication number: 20240350445
    Abstract: The present invention provides anti-fungal compositions comprising at least one unsaturated fatty acid or a pharmaceutically acceptable salt thereof: at least one alpha-hydroxy acid or a pharmaceutically acceptable salt thereof; and at least one amino alcohol.
    Type: Application
    Filed: August 3, 2022
    Publication date: October 24, 2024
    Inventors: Jan Willem TOEBES, Nicholas Philip SWAIN
  • CAROTENOID SOLUTIONS AND USES THEREOF
    Publication number: 20240350446
    Abstract: Provided herein are aqueous solutions and pharmaceutical compositions comprising ionizable carotenoids such as trans-crocetin. The provided compositions have uses in treating diseases, disorders and conditions associated with, but not limited to, infection, ARDS, endotoxemia, inflammation, sepsis, ischemia, hypoxia, shock, stroke, lung injury, wound healing, traumatic injury, reperfusion injury, cardiovascular disease, kidney disease, liver disease, inflammatory disease, metabolic disease, pulmonary disorders, blood related disorders and hyperproliferative diseases such as cancer. Methods of making, and using the aqueous solutions and pharmaceutical compositions are also provided.
    Type: Application
    Filed: April 9, 2021
    Publication date: October 24, 2024
    Inventors: Clet NIYIKIZA, Victor Mandla MOYO, Zhaohua Richard HUANG
  • DELIVERY METHODS FOR TREATING BRAIN AND CENTRAL NERVOUS SYSTEM DISEASES
    Publication number: 20240350447
    Abstract: Described herein are compositions and methods for the topical administration of various compounds to the periorbital and eyelid region of the eye. Such compositions and methods are useful for treating various brain and central nervous system diseases and disorders, as well as in promoting general brain and central nervous system health.
    Type: Application
    Filed: November 23, 2022
    Publication date: October 24, 2024
    Inventors: Weizhen WANG, Nonna SNIDER
  • DICHLOROACETIC ACID CONJUGATING DIPHENYL ETHANE COMPOUND, AND PREPARATION METHOD AND APPLICATION THEREOF
    Publication number: 20240350448
    Abstract: Described herein is a dichloroacetic acid conjugating diphenyl ethane compound, and a preparation method and an application thereof. The dichloroacetic acid conjugating diphenyl ethane compound has a stable structure, low toxicity, a simple preparation process and a high yield, without necessity to preserve it in a dark place, and has anti-tumor activity against a variety of tumor cells cultured in vitro, and the anti-tumor effect in vivo.
    Type: Application
    Filed: June 28, 2024
    Publication date: October 24, 2024
    Inventors: Fanhong WU, Jinwen HUANG, Kangyan XUE, Hui NIE, Fuli LIU, Hui TANG
  • PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF A CANCER
    Publication number: 20240350449
    Abstract: A pharmaceutical combination comprising (A): a polyunsaturated fatty acid and (B): a chemotherapeutic agent compound for the simultaneous, separate or sequential use in the treatment of a cancer in a human patient.
    Type: Application
    Filed: July 3, 2024
    Publication date: October 24, 2024
    Applicant: ABILITY PHARMACEUTICALS S.L.
    Inventors: Carles DOMÈNECH GARCIA, José Alberto ALFÓN CORIAT, Héctor PÉREZ MONTOYO, Miguel Francisco SEGURA GINARD, Jose Miguel LIZCANO DE VEGA
  • COMPOSITION COMPRISING a-KETOGLUTARIC ACID (a-KG) AND 5-HYDROXYMETHYL-2-FURFURAL (5-HMF) TO IMPROVE HEMOGLOBIN-MEDIATED OXYGEN SUPPLY
    Publication number: 20240350450
    Abstract: The present invention relates to a method of treating or preventing a disease or condition that benefits from an increased hemoglobin-mediated oxygen supply comprising administering to a subject a pharmaceutical composition comprising ?-ketoglutaric acid (?-KG) and 5-hydroxymethyl-2-furfural (5-HFM).
    Type: Application
    Filed: August 30, 2022
    Publication date: October 24, 2024
    Inventors: Reinhold Wintersteiger, Chrisitian Bücherl-Harrer
  • TREATMENT OF CIRCADIAN RHYTHM DISORDERS
    Publication number: 20240350451
    Abstract: Embodiments of the invention relate to the use of a melatonin agonist in the treatment of free running circadian rhythms in patients, including light perception impaired patients, e.g. blind patients, and to methods of measuring circadian rhythm.
    Type: Application
    Filed: June 25, 2024
    Publication date: October 24, 2024
    Inventors: Marlene Michelle Dressman, John Joseph Feeney, Louis William Licamele, Mihael H. Polymeropoulos
  • CONTROLLING NEUROPATHIC PAIN
    Publication number: 20240350452
    Abstract: The present application describes a method of treating neuropathic pain in a patient. The method includes a step of administering a pharmaceutical composition to the patient. The pharmaceutical composition consists of one or more pharmaceutically acceptable excipients, Palmitoylethanolamide (PEA) ranging from 35 to 80% by weight, one or more naturally occurring Fatty Acid Amide Hydrolase (FAAH) Inhibitors ranging from 0.5 to 40% by weight, and optionally a vitamin and/or a co-enzyme. The combination of PEA and the one or more naturally occurring FAAH inhibitors in the administered pharmaceutical composition act synergistically to reduce neuropathic pain in the patient.
    Type: Application
    Filed: April 19, 2023
    Publication date: October 24, 2024
    Inventors: Ankit Shyam SINGH, Vedprakash MISHRA, Neelima TONGRA
  • METHODS OF TREATING NEUROLOGICAL AND PSYCHIATRIC DISORDERS
    Publication number: 20240350453
    Abstract: The present disclosure relates to methods of treating neurological or psychiatric diseases or disorders, such as schizophrenia. Compound 1, or a pharmaceutically acceptable salt thereof, is an antipsychotic agent with a non-D2 mechanism of action. Adverse events associated with antipsychotic agents that target the D2 dopamine receptor can be reduced by treating disorders with Compound 1, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: February 1, 2024
    Publication date: October 24, 2024
    Applicant: Sumitomo Pharma America, Inc.
    Inventor: Seth Cabot HOPKINS
  • BACTERIAL EFFLUX PUMP INHIBITORS AND METHODS OF USE
    Publication number: 20240350454
    Abstract: Disclosed herein are bacterial efflux inhibitor compounds and methods of using the compounds for treating bacterial infection.
    Type: Application
    Filed: June 2, 2022
    Publication date: October 24, 2024
    Inventors: Corrella S. DETWEILER, Amy L. CROOKS, Urs OCHSNER, Xicheng SUN, James M. GRAHAM, Christina WONG
  • COMPOSITIONS AND METHODS COMPRISING A COMBINATION OF SEROTONERGIC DRUGS
    Publication number: 20240350455
    Abstract: This disclosure pertains to new compositions and methods comprising a first serotonergic drug and a second serotonergic drug. In one embodiment, the compositions disclosed herein are used for a method of regulating a neurotransmitter receptor, e.g., a serotonin receptor. In one embodiment, the compositions disclosed herein comprise purified compounds, e.g., a purified psilocybin derivative, a purified cannabinoid, a purified terpene, a purified tryptamine, purified LSD, and/or purified MDMA.
    Type: Application
    Filed: April 8, 2024
    Publication date: October 24, 2024
    Applicant: CAAMTECH, INC.
    Inventor: Andrew R. CHADEAYNE
  • COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING INFLAMMATORY CONDITIONS
    Publication number: 20240350456
    Abstract: Compositions and methods useful for the diagnosis and treatment of leaky gut syndrome and IBD including Crohn's disease are disclosed.
    Type: Application
    Filed: April 10, 2024
    Publication date: October 24, 2024
    Applicant: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY
    Inventors: Ronaldo P. Ferraris, Nan Gao, Wei Vivian Li
  • METHODS FOR TREATING HETEROTOPIC OSSIFICATION
    Publication number: 20240350457
    Abstract: The invention features dosing regimens and pharmaceutical formulations for oral administration of palovarotene. The dosing regimens can reduce heterotopic ossification, reduce the number of flare-ups, and/or reduce the severity of flare-ups in subjects suffering from fibrodysplasia ossificans progressiva.
    Type: Application
    Filed: June 28, 2024
    Publication date: October 24, 2024
    Inventors: Clarissa DESJARDINS, Donna Roy Grogan, Jeffrey Neal Packman, Mark Harnett
  • 14-3-3 PROTEIN MODULATORS AS ANTITUMOR AGENTS
    Publication number: 20240350458
    Abstract: The invention relates to a 2-oxoindole compound of Formula (I) or a pharmaceutically acceptable salt thereof, wherein R1 and R2 are, independently from each other, hydrogen, 1H-imidazolyl, thienyl and 1-methyl-1H-imidazolyl, 2-methyl-1H-imidazolyl, 2-aminopyridinyl, 1H-pyrazolyl, with the proviso that one of R1 and R2 is hydrogen; or R1 and R2 together form 9H-fluorene R3 is hydrogen, (C1-C3)alkyl, halogen or NO2; for use as a 14-3-3 protein modulator of a tumor selected from the group consisting of a lymphoma, chronic lymphocytic leukaemia (CLL), Ewing sarcoma, colon cancer, melanoma and anaplastic thyroid cancer (ATC). The invention relates also new 2-oxoindole compound of Formula (I) or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: July 21, 2022
    Publication date: October 24, 2024
    Inventors: Simona Rapposelli, Eugenio Gaudio, Fabrizio Dal Piaz
  • STABLE PHARMACEUTICAL COMPOSITIONS OF BENDAMUSTINE
    Publication number: 20240350459
    Abstract: Stable, injectable pharmaceutical compositions are provided, which are useful as ready-to-dilute (RTD) or ready-to-use (RTU) liquid injectable compositions comprising bendamustine or a pharmaceutically acceptable salt thereof, and which are suitable for intravenous administration. Preferably, solution formulations comprise (a) bendamustine, or pharmaceutically acceptable salts, solvates, or hydrates thereof, (b) at least one pharmaceutically acceptable non-aqueous solvent; (c) optionally, at least one pharmaceutically acceptable excipient, and (d) optionally, a pH adjuster, where the pharmaceutical composition is antioxidant-free, and formulated as a ready-to-dilute or ready-to-use liquid composition suitable for parenteral administration. The invention further relates to methods for manufacturing stable, antioxidant-free injectable solutions of bendamustine.
    Type: Application
    Filed: June 28, 2024
    Publication date: October 24, 2024
    Applicant: SLAYBACK PHARMA LLC
    Inventors: Harish Govindaraja Setty Chinnari, Somashekhar Battini, Sumitra Ashokkumar Pillai, Lourdu Chinnu Thippabattuni, Satheesh Balasubramanian
  • APPLICATION OF HYDRAZIDE COMPOUND IN TUMOR TREATMENT
    Publication number: 20240350460
    Abstract: The present invention relates to an application of a hydrazide compound in tumor treatment, and, in particular, the present invention provides a use of a compound represented by formula I, an optical isomer or a racemate thereof, or a solvate thereof, or a pharmaceutically acceptable salt thereof, being used for the preparation of a composition or formulation, said composition or formulation being used for the prevention and/or treatment of tumors. The compound of the present invention has significant and exceptional therapeutic effects on tumors having low or no expression of the NNMT gene, high expression of DNA methylase, high expression of UHRF1, high methylation level at the NNMT gene nucleotide site, and/or high methylation level at a DNA CpG site in the NNMT gene region.
    Type: Application
    Filed: August 18, 2022
    Publication date: October 24, 2024
    Applicant: NANJING SHIJIANG MEDICINE TECHNOLOGY CO., LTD
    Inventors: Yufeng SHI, Wenjiang MA
  • SERINE PROTEASE INHIBITOR FOR TREATING CORONAVIRUS INFECTION
    Publication number: 20240350461
    Abstract: The disclosure is directed to WX-671, as (L)- or (D)-enantiomers, and as E- or (Z)-isomers or (E/Z)-mixtures, and as free bases or as salts thereof, in preparing medicines for treating coronavirus infection or preventing diseases caused by coronavirus infection, and a medicine for preventing coronavirus infection or preventing diseases caused by coronavirus infection.
    Type: Application
    Filed: January 30, 2024
    Publication date: October 24, 2024
    Inventors: Dror Ben-Asher, Reza Fathi
  • METHODS OF ADMINISTERING IMMUNOSUPPRESSANTS HAVING A SPECIFIED PHARMACODYNAMIC EFFECTIVE LIFE AND THERAPEUTIC MACROMOLECULES FOR THE INDUCTION OF IMMUNE TOLERANCE
    Publication number: 20240350462
    Abstract: This invention relates to methods that provide immunosuppressants and therapeutic macromolecules that are administered within a pharmacodynamically effective window of the immunosuppressants to induce immune tolerance to the therapeutic macromolecules. The methods allow shifting the immune response in favor of tolerogenic immune response development specific to the therapeutic macromolecule.
    Type: Application
    Filed: December 1, 2023
    Publication date: October 24, 2024
    Applicant: Selecta Biosciences, Inc.
    Inventor: Takashi Kei Kishimoto
  • SMALL MOLECULE COMPOUNDS
    Publication number: 20240350463
    Abstract: Disclosed herein are pharmaceutical compositions comprising biosynthetic allosteric mTOR inhibitors that can have improved pharmacology and reduced toxicity. Also disclosed herein are methods of treating a condition or disease by administering biosynthetic allosteric mTOR inhibitors.
    Type: Application
    Filed: June 24, 2022
    Publication date: October 24, 2024
    Inventors: Edmund Graziani, Jay Keasling, Bo Pang, Alan Mathiowetz
  • METHODS OF TREATING NEUROLOGICAL, MUSCULAR, AND PROLIFERATIVE DISORDERS
    Publication number: 20240350464
    Abstract: This disclosure relates to methods of treating neurological, muscular, and proliferative disorders using a combination of metformin and rapamycin.
    Type: Application
    Filed: April 17, 2024
    Publication date: October 24, 2024
    Inventors: Alla Zozulya Weidenfeller, Rosa Maria Da Silva Oliveira, Iryna Fingerhut
  • METHODS FOR SELECTING AN INTRACRANIAL ATHEROSCLEROTIC DISEASE PATIENT FOR TREATMENT
    Publication number: 20240350465
    Abstract: The present invention features methods for selecting treatment for a patient having suffered a minor stroke or transient ischemic attack (TIA) associated with intracranial atherosclerotic disease (ICAD).
    Type: Application
    Filed: August 4, 2021
    Publication date: October 24, 2024
    Inventor: David J. SCHNEIDER
  • COMPOSITIONS OF 1-(4-BROMO-5-(1-ETHYL-7-(METHYLAMINO)-2-OXO-1,2-DIHYDRO-1,6-NAPHTHYRIDIN-3-YL)-2-FLUOROPHEYL)-3-PHENYLUREA
    Publication number: 20240350466
    Abstract: Provided herein are low impurity compositions comprising a compound represented by Formula (I): which are useful in the treatment of disorders related to the activity of the c-KIT and PDGFR? kinases, and oncogenic forms thereof.
    Type: Application
    Filed: June 28, 2024
    Publication date: October 24, 2024
    Inventors: Michael D. Kaufman, Scott Bone, Corey Bloom, Fred Jordan
  • [6R]-MTHF IN B6 ENHANCED 5-FU BASED CHEMOTHERAPY OF PANCREATIC CANCER
    Publication number: 20240350467
    Abstract: The present invention relates to the treatment of pancreatic cancer, in particular KRAS-mutated pancreatic adenocarcinoma, in human populations employing a dosage regimen which includes arfolitixorin ([6R]-5,10-methylenetetrahydrofolate ([6R]-MTHF) and a B6 vitamin in connection with 5-fluorouracil (5-FU) based chemotherapy.
    Type: Application
    Filed: April 20, 2023
    Publication date: October 24, 2024
    Inventors: Per Lennart Lindberg, David Machover
  • MALEATE SALT OF THE FREE BASE OF N-[5-(AMINOSULFONYL)-4-METHYL-1,3-THIAZOL-2-YL]-N-METHYL-2-[4-(2-PYRIDINYL)-PHENYL]-ACETAMIDE, PHARMACEUTICAL FORMULATIONS, METHODS OF MANUFACTURE AND USES THEREOF
    Publication number: 20240350468
    Abstract: The present invention relates to the field of anti-viral active agents, particularly to salts, more particularly to a maleate salt of the free base of N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)-phenyl]-acetamide, to pharmaceutical formulations thereof as well as to methods for the production of these salts. The present invention also relates to the use of theses salts and of respective pharmaceutical formulations thereof in methods of treatment and/or prevention of human herpes simplex virus infections, particularly infections caused by HSV-1 and HSV-2.
    Type: Application
    Filed: June 24, 2024
    Publication date: October 24, 2024
    Applicant: AICURIS GMBH & CO. KG
    Inventors: Yogeshwar BACHHAV, Wilfried SCHWAB, Alexander BIRKMANN, Susanne BONSMANN, Thomas GOLDNER
  • TREATMENT OF LOWER RESPIRATORY TRACT INFECTION WITH TRADIPITANT
    Publication number: 20240350469
    Abstract: Disclosed herein is a method of treatment of a lower respiratory tract infection caused by. e.g., coronavirus disease (COVID-19), influenza, or other virus. comprising treatment with the NK-1 receptor antagonist. tradipitant.
    Type: Application
    Filed: August 24, 2022
    Publication date: October 24, 2024
    Inventors: Christos Polymeropoulos, Vasilios Polymeropoulos, Sandra P. Smieszek, Bartlomiej P. Przychodzen, Gunther Birznieks, Mihael H. Polymeropoulos
  • SUSTAINED-RELEASE MICROSPHERE COMPRISING DONEPEZIL
    Publication number: 20240350470
    Abstract: Disclosed is an injection including donepezil-containing microspheres.
    Type: Application
    Filed: August 5, 2022
    Publication date: October 24, 2024
    Applicant: WHAN IN Pharmaceutical Co., LTD.
    Inventors: Byung-hyuck KIM, Chan-eun JUNG, Hyuk-il KWON, Ho-chul SHIN, Yong-soon HONG, Ju-hyun KIM
  • PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING ATTENTION DEFICIT/HYPERACTIVITY DISORDER
    Publication number: 20240350471
    Abstract: The present invention relates to a pharmaceutical composition for preventing or treating attention deficit/hyperactivity disorder (ADHD), including SNAP5114 as an active ingredient. A Git1 gene-deficient hetero (+/?) mouse, confirmed to have increased amount of GABA in the brain striatum that controls hyperactivity, can be used as an animal model of ADHD, and by confirming that hyperactivity is ameliorated by administering SNAP5114 to the Git1 gene-deficient hetero (+/?) mouse, SNAP5114 is provided as a therapeutic agent for ADHD.
    Type: Application
    Filed: August 20, 2021
    Publication date: October 24, 2024
    Applicants: DANKOOK UNIVERSITY CHEONAN CAMPUS INDUSTRY ACADEMIC COOPERATION FOUNDATION, INSTITUTE FOR BASIC SCIENCE
    Inventors: Bo-Eun Yoon, C. Justin Lee, Yoo Sung Kim, Moonsun Sa
  • Synergistic Compositions for Gynecological Procedures
    Publication number: 20240350472
    Abstract: Synergistic compositions for use in treatment during gynecological procedures are provided. Synergistic compositions that enable practitioners to perform gynecological procedures without pain or bleeding to patients are provided.
    Type: Application
    Filed: July 1, 2024
    Publication date: October 24, 2024
    Inventor: Pathyil Damoderam Krishna Kumar
  • STABLE NIMODIPINE PARENTERAL FORMULATION
    Publication number: 20240350473
    Abstract: A nimodipine injection concentrate and diluted formulation comprises nimodipine (base or salt), an effective amount of a hydrophilic surfactant, and a pharmaceutically acceptable carrier for injection which is an aqueous solution substantially free of organic solvent, such that the nimodipine is substantially contained in a concentrated injection solution, suspension, emulsion or complex as a micelle or a colloidal particle or an inclusion complex and the formulation is stable and clear. In certain embodiments, the hydrophilic surfactant is polysorbate 80.
    Type: Application
    Filed: June 28, 2024
    Publication date: October 24, 2024
    Applicant: ACASTI PHARMA U.S., INC.
    Inventors: S. George Kottayil, Amresh Kumar, Prasanna Sunthankar, Vimal Kavuru, Kamalkishore Pati
  • ANTIBODY-DRUG CONJUGATES AND USES THEREOF
    Publication number: 20240350474
    Abstract: The present invention relates to therapeutic immunoconjugates comprising SN-38 attached to an antibody or antigen-binding antibody fragment. The antibody may bind to Trop-2 or CEACAM5 and the immunoconjugate may be administered at a dosage of between 4 mg/kg and 16 mg/kg, preferably 4, 6, 8, 9, 10, 12, or 16 mg/kg. When administered at specified dosages and schedules, the immunoconjugate can reduce solid tumors in size, reduce or eliminate metastases and is effective to treat cancers resistant to standard therapies, such as radiation therapy, chemotherapy or immunotherapy. Surprisingly, the immunoconjugate is effective to treat cancers that are refractory to or relapsed from irinotecan.
    Type: Application
    Filed: June 28, 2024
    Publication date: October 24, 2024
    Inventors: David M. Goldenberg, Serengulam V. Govindan
  • TRIGONELLINE MITIGATES CARDIOMYOPATHY CAUSED BY SARS-COV-2 SPIKE PROTEIN UNDER OBESITY
    Publication number: 20240350475
    Abstract: Described herein are methods, systems, and pharmaceutical compositions for using Trigonelline (TRG), an alkaloid found in the seeds of many plants, including coffee beans, to attenuate Spike-protein exacerbated lipotoxicity and mitochondria stress in endothelial cells and cardiomyocytes to protect the heart from injuries caused by SARS-CoV-2 Spike protein under obesity.
    Type: Application
    Filed: February 13, 2024
    Publication date: October 24, 2024
    Applicant: University of South Carolina
    Inventors: Wenbin Tan, Vi Nguyen, Taixing Cui
  • Smoking Cessation Aid
    Publication number: 20240350476
    Abstract: Disclosed herein are smoking cessation products comprising 6-methylnicotine and methods of treating nicotine addiction using a smoking cessation production comprising 6-methylnicotine.
    Type: Application
    Filed: March 28, 2024
    Publication date: October 24, 2024
    Inventors: Ryan Tanakit, Samy Hamdouche, David Renteln, Tod Miller
  • Method of Treating Renal Cell Carcinoma Using N-(4-(6,7-dimethoxyquinolin-4-yloxy)phenyl)-N’-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, (2S)-hydroxybutanedioate
    Publication number: 20240350477
    Abstract: The present disclosure relates to a method of treating advanced renal cell carcinoma (RCC) in human patients who have received prior anti-angiogenic therapy using CABOMETYX, a kinase inhibitor.
    Type: Application
    Filed: July 26, 2023
    Publication date: October 24, 2024
    Inventors: Dana T. Aftab, Gisela Schwab, Colin Hessel, Christian Scheffold, Steven Lacy, Dale Miles, Alan Arroyo, Mark Dean
  • APPLICATION OF BENZISOQUINOLINE DIKETONE COMPOUND IN TREATMENT OF TUMOR
    Publication number: 20240350478
    Abstract: The present invention relates to an application of a benzisoquinoline diketone compound in the treatment of a tumor. Specifically, the present invention provides a use of a compound of formula (I), or an optical isomer or racemate thereof, or a solvate thereof, or a pharmaceutically acceptable salt thereof, or a deuterated compound thereof, i.e., a use in the preparation of a composition or preparation, the composition or preparation being used for preventing and/or treating a tumor. The compound of the present invention has significant and excellent therapeutic effects on tumors having low or no expression of an NNMT gene, high expression of a DNA methylase, high expression of UHRF1, a high methylation level at a nucleotide site of the NNMT gene, and/or a high methylation level at a DNA CpG site of an NNMT gene region.
    Type: Application
    Filed: August 18, 2022
    Publication date: October 24, 2024
    Applicant: NANJING SHIJIANG MEDICINE TECHNOLOGY CO., LTD
    Inventors: Yufeng SHI, Wenjiang MA
  • Systems and Methods for Treating an Opioid-Induced Adverse Pharmacodynamic Response
    Publication number: 20240350479
    Abstract: Disclosed in certain embodiments is a method of treating or preventing an opioid-induced adverse pharmacodynamic response comprising administering to a patient in need thereof an effective amount of buprenorphine.
    Type: Application
    Filed: February 8, 2024
    Publication date: October 24, 2024
    Inventors: Michele Hummel, Donald J. Kyle, Garth Whiteside
  • STABLE PHARMACEUTICAL COMPOSITION OF METHYLNALTREXONE FOR AN ORAL ADMINISTRATION
    Publication number: 20240350480
    Abstract: The present invention relates to a stable pharmaceutical composition comprising methylnaltrexone and its pharmaceutically acceptable salts. The invention further relates to compositions comprising of methylnaltrexone and its pharmaceutically acceptable salts and ion exchange resin and its process of preparation. The compositions are substantially free of impurities. The compositions provide the desired immediate release of methylnaltrexone and were found to be stable under accelerated stability conditions. The compositions are administered orally once daily for the treatment of opioid-induced constipation in adult patients with cancer and chronic non-cancer pain.
    Type: Application
    Filed: April 18, 2024
    Publication date: October 24, 2024
    Applicant: Lupin Limited
    Inventors: Brijesh Purohit, Anirudha Bhagirath Kute, Sajeev Chandran, Makarand Krishnakumar Avachat, Ashish Deshmukh
  • USE OF N-MYRISTOYL TRANSFERASE (NMT) INHIBITORS IN THE TREATMENT OF CANCER, AUTOIMMUNE DISORDERS, AND INFLAMMATORY DISORDERS
    Publication number: 20240350481
    Abstract: The use of N-myristoyl-transferase (NMT) inhibitors in the treatment of cancer, autoimmune disorders, and inflammatory disorders is disclosed. With respect to cancer, the preferred cancer to be treated is B-cell lymphoma, and the NMT used is PCLX-001 (DDD86481, CAS RN 1215011-08-7). Preferred NMT inhibitors for the treatment of autoimmune and inflammatory disorders include the aforementioned PCLX-001, PCLX-002 (DDD85646, CAS RN 1215010-55-10), and IMP-1088 (CAS RN 2059148-82-0), and the disorders to be treated include rheumatoid arthritis, asthma, gastritis, colitis, and other digestive and respiratory ailments.
    Type: Application
    Filed: October 20, 2021
    Publication date: October 24, 2024
    Inventors: Luc G. BERTHIAUME, Erwan BEAUCHAMP
  • SMALL MOLECULE BAX INHIBITORS AND USES THEREOF
    Publication number: 20240350482
    Abstract: Compounds, compositions and method of using these compounds are disclosed for treating a disease or disorder in which it is desirable to inhibit BAX, such as a cardiovascular disease or disorder.
    Type: Application
    Filed: March 5, 2024
    Publication date: October 24, 2024
    Inventors: Evripidis Gavathiotis, Richard N. Kitsis, Thomas Peter Garner, Dulguun Amgalan, Lorrie Kirshenbaum, Felix Kopp
  • COMBINATION THERAPY FOR THE TREATMENT OF PSYCHIATRIC DISORDER
    Publication number: 20240350483
    Abstract: The present invention provides for a method of treating a person suffering from a psychiatric disorder that includes administration of a pharmaceutically effective amount of (i) nefazodone, or a pharmaceutically acceptable salt thereof, and (ii) risperidone. Also provided is a unit dose that includes (i) nefazodone, or a pharmaceutically acceptable salt thereof, (ii) risperidone, and (iii) one or more pharmaceutically acceptable excipients. Also provided is a therapeutic package that includes (a) the unit doses, (b) a finished pharmaceutical container that contains the unit doses, (c) printed indicia, and (d) optionally an outside container containing the finished pharmaceutical container and the printed indicia.
    Type: Application
    Filed: April 11, 2024
    Publication date: October 24, 2024
    Inventors: Sandeep Gaonkar, Kara Moutvic, Paul Sudhakar, Scott Boyer
  • METHODS OF USING SPLICING MODULATORS
    Publication number: 20240350484
    Abstract: This disclosure relates to methods for the treatment of neoplastic disorders by administering Compound 1, or a pharmaceutically acceptably salt thereof, on its own and/or as part of a conjugate or composition, and inducing production of at least one neoantigen.
    Type: Application
    Filed: April 25, 2024
    Publication date: October 24, 2024
    Inventors: Ermira PAZOLLI, Silvia BUONAMICI, James PALACINO, Michael SEILER, Ping ZHU, Evan BARRY, Lihua YU